<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521845</url>
  </required_header>
  <id_info>
    <org_study_id>90-1-94-8048</org_study_id>
    <nct_id>NCT01521845</nct_id>
  </id_info>
  <brief_title>Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>Phase 3 Study of Poly Unsaturated Fatty Acids of Omega 3 as an Anti Platelet Agent on Biomarkers of Cardiac Necrosis Including CKMB and Troponin I and Inflammation Marker CRP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of omega 3 on biomarkers of cardiac
      necrosis(CKMB and troponin I) and inflammation marker CRP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) has become the most common form of coronary
      revascularization worldwide. Although PCI is a safe procedure, it may have multiple risks
      including bleeding, coronary dissection, abrupt vessel closure, and myocardial necrosis. It
      is estimated that approximately 25% of patients undergoing PCI have significant
      postprocedural creatinine kinase (CK)/creatinine kinase myocardial band (CK-MB) elevations
      and approximately 50% of patients have significant post-procedural troponin elevations.
      Initially, it was felt these elevations were simple enzyme leaks with no long-term
      implications.

      Now, several studies have demonstrated that periprocedural infarction is associated with
      short-, intermediate-, and long-term adverse outcomes, most notably mortality. Pretreatment
      with antiplatelets such as aspirin and clopidogrel play an important role in reducing
      cardiovascular events (CV events) following PCI.

      Omega -3 polyunsaturated fatty acids (PUFAs) have antiplatelet effect. It may also improve
      response to aspirin and clopidogrel in low-response patients.

      This study is a randomized clinical trial (RCT) evaluating the effect of omega 3 supplement
      [with 400mg Eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA)] on biomarkers of
      cardiac necrosis (CKMB and troponin I) in patients undergoing elective PCI. Eighty patients
      planed to do elective PCI will be categorized into two groups. The first group will be
      received standard regimen for PCI (aspirin, clopidogrel, and heparin) and the second group
      will be treated with standard regimen in addition to 3 gram omega 3 (12 hours before PCI).
      Blood samples will be drawn in all patients before and 8 and 24 h after intervention for
      cardiac biomarkers assessment (CK-MB, troponin I)and inflammation marker C-reactive protein
      (CRP). Major adverse cardiac events (MACE) will be evaluated as a second endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Necrosis Biomarkers (CKMB, Troponin I)</measure>
    <time_frame>8 and 24 hrs after percutaneous coronary intervention</time_frame>
    <description>difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation Marker (CRP)</measure>
    <time_frame>8 and 24 hrs after percutaneous coronary intervention</time_frame>
    <description>difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE(Major Adverse Cardiac Effect) Defined as Need for Target Revascularization, Myocardial Infarction and Death</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>omega 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive omega 3 in addition to standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group is without omega 3 : just receives standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega 3</intervention_name>
    <description>3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI</description>
    <arm_group_label>omega 3</arm_group_label>
    <other_name>fish oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  candidate of elective PCI

          -  treatment with aspirin at least 5 days before PCI

        Exclusion Criteria:

          -  high CKMB and troponin I level

          -  cardiac bypass in recent 3 months

          -  platelet count &lt; 70Ã—10 9/L

          -  sever chronic renal failure

          -  active bleeding

          -  treatment with glycoprotein IIb/IIIa inhibitors during PCI

          -  treatment with bivalirudin during PCI

          -  sensitivity to aspirin and clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Salamzadeh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SBMU School of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>farzaneh foroughinia, phD</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moddaress Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <results_first_submitted>May 31, 2012</results_first_submitted>
  <results_first_submitted_qc>June 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2012</results_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jamshid Salamzadeh, PhD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>elective percutaneous coronary intervention</keyword>
  <keyword>hs-CRP</keyword>
  <keyword>CKMB and troponin I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omega 3</title>
          <description>receive omega 3 in addition to standard treatment</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>This group is without omega 3 : just receives standard treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omega 3</title>
          <description>receive omega 3 in addition to standard treatment</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>This group is without omega 3 : just receives standard treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="11"/>
                    <measurement group_id="B2" value="60" spread="11"/>
                    <measurement group_id="B3" value="61" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Necrosis Biomarkers (CKMB, Troponin I)</title>
        <description>difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention</description>
        <time_frame>8 and 24 hrs after percutaneous coronary intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega 3</title>
            <description>receive omega 3 in addition to standard treatment</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>This group is without omega 3 : just receives standard treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Necrosis Biomarkers (CKMB, Troponin I)</title>
          <description>difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="18"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammation Marker (CRP)</title>
        <description>difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention</description>
        <time_frame>8 and 24 hrs after percutaneous coronary intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega 3</title>
            <description>receive omega 3 in addition to standard treatment</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>This group is without omega 3 : just receives standard treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Marker (CRP)</title>
          <description>difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention</description>
          <units>mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MACE(Major Adverse Cardiac Effect) Defined as Need for Target Revascularization, Myocardial Infarction and Death</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega 3</title>
            <description>receive omega 3 in addition to standard treatment</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>This group is without omega 3 : just receives standard treatment</description>
          </group>
        </group_list>
        <measure>
          <title>MACE(Major Adverse Cardiac Effect) Defined as Need for Target Revascularization, Myocardial Infarction and Death</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>not comparable</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omega 3</title>
          <description>receive omega 3 in addition to standard treatment</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>This group is without omega 3 : just receives standard treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Jamshid Salamzadeh</name_or_title>
      <organization>Shaheed Beheshti Medical University</organization>
      <phone>00982188662334</phone>
      <email>j.salamzadeh@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

